Deutsche Bank tracker shows US slowdown for Novo's Wegovy pill
Novo Nordisk shares fell 2.5% to DKK319.20 after the bank flagged weakening oral Wegovy scripts in IQVIA data through 26 June.
MH
By Maren Holt · Senior Reporter, GLP-1
Jul 8 03:00 ETSource: Proactive financial news
The wire
- 01Deutsche Bank's weekly prescription tracker, using IQVIA data to 26 June, singled out loss of momentum for the oral Wegovy formulation and modelled single-digit full-year downside.
- 02Oral semaglutide uptake is the key test of whether pills displace weekly injections, which affects dispensing patterns and telehealth demand mix.
- 03The bank sees double-digit downside for injectable Wegovy and Rybelsus but double-digit upside for Ozempic; these are analyst extrapolations, not company-reported sales.
From the source
Read at proactiveinvestors.comNovo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown
Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed i